Previous 10 | Next 10 |
Matinas BioPharma Holdings, Inc. Q1 2019 Earnings Conference Call May 14, 2019 8:30 AM Company Participants Jenene Thomas - IR Jerry Jabbour - Chief Executive Officer Conference Call Participants Robert Hazlett - BTIG Presentation Operator Greetings and welcome to ...
BEDMINSTER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2019 and provided an update on its corporate activities and product pi...
BEDMINSTER, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 14, 2019 at 8:30 a.m. ET to discuss oper...
BEDMINSTER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to ring the NYSE Opening Bell® on Monday, May 6 th , 2019 at 9:30 AM E.T., to commemorate a tr...
BEDMINSTER, N.J., May 01, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D., Chief Development Officer of the Company, was selected to present a corporate overview an...
Sydney, Australia (ABN Newswire) - Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma, (NYSE:MTNB). Matinas BioPharma proprietary, disruptive technology utilizes a lipid nano-crystal (LNC) platform technology which can encapsulate small molecule dr...
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2018 Earnings Conference Call April 2, 2019 08:00 AM ET Company Participants Jenene Thomas - IR Jerry Jabbour - CEO Raphael Mannino - CSO James Ferguson - Chief Medical Officer Theresa Matkovits - Chief Development Officer Keith ...
– Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3 market – – Company continues to drive development of proprietary and highl...
Matinas Biopharma Holdings (NYSEMKT: MTNB ): FY GAAP EPS of -$0.15 misses by $0.02 . Revenue of $0.12M (-20.0% Y/Y) Shares +3% AH. Press Release More news on: Matinas BioPharma Holdings, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
In a re-examination of its original recommendation released in December 2018, the European Medicines Agency's advisory group CHMP confirms its view that omega-3 fatty acid medicines containing a combination of an ethyl ester of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...